← Back to guidelines
Cardiology15 papers

Chronic eosinophilic leukemia

Last edited: 4/22/2026

Overview

Chronic eosinophilic leukemia is a myeloproliferative neoplasm characterized by persistent eosinophilia and associated with a risk of tissue damage and organ dysfunction 1.

Diagnosis

  • Persistent peripheral blood eosinophilia (≥10% eosinophils) 1
  • Evidence of bone marrow eosinophilia 1
  • Presence of dysplastic or clonal abnormalities in eosinophils 1
  • Exclusion of other causes of secondary eosinophilia 1
  • Cytogenetic or molecular markers (e.g., FIP1L1-PDGFRA fusion gene) may aid diagnosis 1
  • Management

  • First-line treatment: Corticosteroids for symptomatic relief and control of eosinophilia 1
  • Targeted therapy: Tyrosine kinase inhibitors such as imatinib for FIP1L1-PDGFRA fusion-positive cases 1
  • Adjunctive treatments: Consider hematopoietic stem cell transplantation in younger patients with aggressive disease 1
  • Special Populations

  • Immunodeficiency considerations: Patients with underlying immunodeficiencies (e.g., ataxia telangiectasia) may require tailored management approaches 1
  • No specific pediatric, pregnancy, or elderly guidelines provided 1
  • Key Recommendations

  • Initiate corticosteroid therapy for symptomatic control and management of eosinophilia in chronic eosinophilic leukemia (Evidence: Moderate) 1
  • Evaluate for specific genetic markers like FIP1L1-PDGFRA fusion gene to guide targeted therapy selection (Evidence: Moderate) 1
  • Consider hematopoietic stem cell transplantation in eligible younger patients with aggressive disease progression (Evidence: Expert opinion) 1
  • References

    1 Zagami AS, Colebatch HJ, Wakefield D. Chronic eosinophilic pneumonia in a patient with ataxia telangiectasia. Australian and New Zealand journal of medicine 1987. link

    Original source

    1. [1]
      Chronic eosinophilic pneumonia in a patient with ataxia telangiectasia.Zagami AS, Colebatch HJ, Wakefield D Australian and New Zealand journal of medicine (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG